Guardant launches Shield blood-based screening test for CRC in South Korea

Guardant Health announced that it has launched its blood-based colorectal cancer screening test, Shield, in collaboration with Samsung Medical Center in South Korea. Guardant Health’s Shield test, which can be used for regular CRC screening in eligible individuals, is an innovative test that can detect cancer in its early stages by analyzing circulating tumor DNA, which is produced when tumors shed small pieces of their genetic material into the bloodstream. In the pivotal ECLIPSE study, which enrolled over 20,000 patients, the Shield test achieved 83% sensitivity for the detection of colorectal cancer in average-risk adults in the U.S., with specificity of 90%.